Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Aerie Pharmaceuticals stock in Canada | $16.29

Own Aerie Pharmaceuticals shares in just a few minutes.

Aerie Pharmaceuticals, Inc
+$0.06 (+0.35%)

Aerie Pharmaceuticals is a drug manufacturers-specialty & generic business based in the US. Aerie Pharmaceuticals stocks (AERI.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $18.78 – a decrease of 1.51% over the previous week. Aerie Pharmaceuticals employs 365 staff and has a trailing 12-month revenue of around $85.8 million.

How to buy Aerie Pharmaceuticals stock in Canada

  1. Choose a platform. If you're a beginner, our stock trading table below can help you choose.
  2. Open your account. You'll need your ID, bank details and national insurance number.
  3. Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
  4. Search the platform for stock code: AERI in this case.
  5. Research Aerie Pharmaceuticals stocks. The platform should provide the latest information available.
  6. Buy your Aerie Pharmaceuticals stocks. It's that simple.

How has Coronavirus impacted Aerie Pharmaceuticals's stock price?

Since the stock market crash in March caused by coronavirus, Aerie Pharmaceuticals's stock price has had significant negative movement.

Its last market close was $16.29, which is 24.55% down on its pre-crash value of $21.59 and 50.83% up on the lowest point reached during the March crash when the stocks fell as low as $10.8.

If you had bought $1,000 worth of Aerie Pharmaceuticals stocks at the start of February 2020, those stocks would have been worth $581.77 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $787.78.

Aerie Pharmaceuticals stock price

Use our graph to track the performance of AERI stocks over time.

Aerie Pharmaceuticals stocks at a glance

Information last updated 2021-07-30.
Latest market close$16.29
52-week range$9.01 - $21.3
50-day moving average $16.1356
200-day moving average $17.1282
Wall St. target price$27.55
Dividend yield N/A (0%)
Earnings per share (TTM) $-5.169

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Available Asset Types Stock Fee Option Fee Account Fee ETF Transaction Cost Feature Table description
Wealthsimple Trade
Stocks, ETFs
Get a $50 bonus when you open a Wealthsimple Trade account and deposit and trade at least $100.
Pay no commissions when you trade Canadian stocks and ETFs with Wealthsimple Trade.
Scotia iTRADE
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
$9.99 + $1.25 contract ($4.99 + $1.25 contract if completed 150 trades or more a quarter)
$9.99 ($4.99 if completed 150 trades or more a quarter)
Pay no annual account fees.
Buy, sell and trade ETFs, Equities, Options and more with competitive commissions.
CIBC Investor's Edge
Stocks, Bonds, Options, Mutual Funds, ETFs
$4.95 - $6.95
$4.95 - $6.95 (+$1.25 per contract)
$0 if conditions met, otherwise $100/year
$4.95 - $6.95 is applicable for online stock, ETF and option trades only. Pay $4.95 when you qualify as an Active Trader (trade 150+ times per quarter).
An intuitive and easy-to-use platform with access to a variety of tools that help you make smart decisions and trade with confidence.
Interactive Brokers
Stocks, Bonds, Options, ETFs, Currencies, Futures
Min. $1.00, Max. 0.5% of trade value
$1.50 min. per order
Min. $1.00, Max. 0.5% of trade value
Extensive trading capabilities and global investment tracking.
Access market data 24 hours a day, six days a week and invest in global stocks, options, futures, currencies, bonds and funds from one single account.
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
$9.95 + $1 per contract
Get $50 in free trades when you fund your account with a minimum of $1,000.
Opt for self-directed investing and save on fees or get a pre-built portfolio and take some of the guesswork out.
Qtrade Direct Investing
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
$6.95 - $8.75
$6.95 - $8.75 + $1.25 per contract
$0 if conditions met, otherwise $25/quarter
$0 - $8.75
Trade 100 select ETFs free of charge.
Qtrade Direct Investing offers low trading commissions and an easy-to-use platform with access to powerful tools and a wide selection of investment options. Trade 100 ETFs free of charge and thousands more for $8.75 or lower.

Compare up to 4 providers

Online stock trading

Is it a good time to buy Aerie Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Aerie Pharmaceuticals price performance over time

Historical closes compared with the last close of $16.29

1 month (2021-07-02) 1.75%
3 months (2021-04-30) -4.90%

Aerie Pharmaceuticals financials

Revenue TTM USD$85.8 million
Gross profit TTM USD$55.5 million
Return on assets TTM -23.54%
Return on equity TTM -301.15%
Profit margin -205.13%
Book value $0.512
Market capitalisation USD$743.7 million

TTM: trailing 12 months

How to short and sell Aerie Pharmaceuticals stocks

  1. Create a CFD or spread betting account.
  2. Search for the stock code. E.g. "AERI.US"
  3. Choose your position size.
  4. Select "sell" rather than "buy".
  5. Confirm your position and keep tabs on it. You may wish to set limits on your position.

There are currently 5.4 million Aerie Pharmaceuticals stocks held short by investors – that's known as Aerie Pharmaceuticals's "short interest". This figure is 11.8% down from 6.1 million last month.

There are a few different ways that this level of interest in shorting Aerie Pharmaceuticals stocks can be evaluated.

Aerie Pharmaceuticals's "short interest ratio" (SIR)

Aerie Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Aerie Pharmaceuticals stocks currently shorted divided by the average quantity of Aerie Pharmaceuticals stocks traded daily (recently around 572087.64643237). Aerie Pharmaceuticals's SIR currently stands at 9.39. In other words for every 100,000 Aerie Pharmaceuticals stocks traded daily on the market, roughly 9390 stocks are currently held short.

However Aerie Pharmaceuticals's short interest can also be evaluated against the total number of Aerie Pharmaceuticals stocks, or, against the total number of tradable Aerie Pharmaceuticals stocks (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Aerie Pharmaceuticals's short interest could be expressed as 0.11% of the outstanding stocks (for every 100,000 Aerie Pharmaceuticals stocks in existence, roughly 110 stocks are currently held short) or 0.1173% of the tradable stocks (for every 100,000 tradable Aerie Pharmaceuticals stocks, roughly 117 stocks are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the stock price, with fewer people currently willing to bet against Aerie Pharmaceuticals.

Find out more about how you can short Aerie Pharmaceuticals stock.

Aerie Pharmaceuticals stock dividends

We're not expecting Aerie Pharmaceuticals to pay a dividend over the next 12 months. However, you can browse other dividend-paying stocks in our guide.

Aerie Pharmaceuticals stock price volatility

Over the last 12 months, Aerie Pharmaceuticals's stocks have ranged in value from as little as $9.01 up to $21.3. A popular way to gauge a stock's volatility is its "beta".

AERI.US volatility(beta: 0.71)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a stocks volatility in relation to the market. The market (NASDAQ average) beta is 1, while Aerie Pharmaceuticals's is 0.7138. This would suggest that Aerie Pharmaceuticals's stocks are less volatile than average (for this exchange).

Aerie Pharmaceuticals overview

Aerie Pharmaceuticals, Inc., an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma, ocular surface, and retinal diseases in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma. The company is also developing AR-15512 to treat signs and symptoms of dry eye; and AR-1105, AR-13503 SR, and AR-14034 SR sustained-release implants focused on retinal diseases. It has a collaborative research, development, and licensing agreement with DSM. Aerie Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Durham, North Carolina.

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Ask an Expert

You must be logged in to post a comment.

Go to site